Home › Myelofibrosis › Alabama
Pag-aaral pangklinika para sa Myelofibrosis sa Alabama
7 pag-aaral para sa Myelofibrosis ang naghahanap ng mga kalahok sa mga site sa Alabama.
Mga Lungsod sa Alabama
Opisyal na teksto ng pag-aaral (English)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Alabama, Birmingham
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT04176198Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Alabama At Birmingham, Birmingham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT07441694UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
- University of Alabama at Birmingham, Birmingham
Nagre-recruitPhase 1
4 Weeks – 75 Years · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT06047886A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Alabama Birmingham, Birmingham
Nagre-recruitPhase 2
Edad 18 hanggang 66 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06859424SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UAB Hospital, Birmingham
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2025 · NCT06479135Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- University of Alabama at Birmingham, Birmingham
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 21, 2023 · NCT05280509Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.